Sanofi Earnings

Sanofi’s revenue fell -4.61% since last year same period to $10606Mn in the Q1 2025. On a quarterly growth basis, Sanofi has generated 38.99% jump in its revenue since last 3-months.

Sanofi’s net profit jumped 65.23% since last year same period to $1872Mn in the Q1 2025. On a quarterly growth basis, Sanofi has generated 275.15% jump in its net profits since last 3-months.

Sanofi’s net profit margin jumped 73.2% since last year same period to 17.65% in the Q1 2025. On a quarterly growth basis, Sanofi has generated 169.92% jump in its net profit margins since last 3-months.

Sanofi’s price-to-earnings ratio after this Q1 2025 earnings stands at 18.49.

Sanofi’s earning per share (EPS) estimates for the current quarter stand at 0.95 - a 29.39% jump from last quarter’s estimates.

Sanofi’s earning per share (EPS) estimates for the current year stand at 0.95.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Sanofi’s return on assets (ROA) stands at 0.04.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Sanofi’s return on equity (ROE) stands at 0.07.